Screen Shot 2021-11-02 at 5.34.55 PM.png

RPR™ Resources

Since 2016, MAT has run close to 700 projects across 45 countries on the RPR platform. Learn about how we have helped our clients expand and deepen their insights - gathering feedback from our global payer network to inform pivotal product development decisions across a range of treatment areas and phases. 

RPR in action

Robust Reviews explore a variety of situations where global pharmaceutical and device manufacturers have leveraged RPR instead of traditional payer research methods. These case studies span treatment areas, development phases, and markets. Interested in learning more? Contact us and a member of our Commercial team will be in touch.

MAT-RR-JAN-22.png

Agile Payer Research

Uncover the power of follow up and clarification questions

Download >

Surrogate Endpoints.png

Surrogate Endpoints

Payers provide a deep understanding of the acceptability of surrogate end-points

Download >

COVID19 Assessment.png

COVID19 Assessment

Up to the minute, critical insights into the Covid-19 market landscape

Download >

Clinical Trial Design.png

Clinical Trial Design

Developing the optimal clinical trial with payer input

Download >

Pricing & Market Access.png

Pricing & Market Access

Gaining invaluable Payer insight into Pricing and Access acceptability

Download >

Multi-Indication.png

Multi-Indication Prioritization

Leveraging  Rapid Payer Response™ (RPR) to prioritize an asset's commercial opportunity across multiple indications in Acute

Download >

Vetting Evidence Generation Plan.png

Evidence Generation Plan

Invaluable payer insight into a TPP and the design for an evidence generation 

Download >

White Papers

Comprehensive reports spanning multiple payer research initiatives give broad insight into trends and themes across the market access landscape

Whitepaper - 1 HTAs.png

Achieving Early Access in Oncology with Non-Comparative Data:

How HTAs approach single arm trial evidence in oncology

Whitepaper 2 Drivers and resistors.png

Achieving Early Access in Oncology with Non-Comparative Data:

Drivers and resistors of acceptance of single arm data

Whitepaper 3 Early access.png

Achieving Early Access in Oncology with Non-Comparative Data:

Early access pathways

Seen at ISPOR

Approved posters from previous ISPOR conferences

2019-VBP.png

ISPOR Europe 2019

Value-based procurement: Understanding how payers approach and implement contracting and procurement of novel treatments based on their value

Download >

2018-RWE.jpg

ISPOR Europe 2018

Understanding the impact of real world evidence on reimbursement decisions across EU5 countries using a web-based portal to engage payers

Download >

2019-COMBO.png

ISPOR Europe 2019

Identifying the key challenges in evaluation and pricing of oncology combination therapies and future policy changes using a web-based portal to engage payers

Download >

2018-CART.jpg

ISPOR Europe 2018

Identifying the key challenges affecting the reimbursement of CAR-T therapies in the EU5 using a web-based portal to engage payers

Download >

2019-CGT.png

ISPOR Europe 2019

Assessing the evolution of the pricing and access landscape for cell and gene therapies in the US and EU3 through a web-based portal to engage payers

Download >

2018-VACCINES.jpg

ISPOR Europe 2018

Identifying the key drivers affecting the reimbursement of therapeutic vaccines in the EU5 using web-based portal to engage payers 

Download >